Pradefovir Mesylate Tablets 45?mg (Xinshumu)

Pradefovir Mesylate Tablets 45?mg (Xinshumu)

(1 customer review)

$1.00

Xinshumu Pradefovir Mesylate Tablets deliver 45?mg of pradefovir per tablet in a 30-tablet bottle. Manufactured by Xi’an Gelan Xintong Pharmaceutical Co., Ltd., with NMPA approval H20240036. Designed for preclinical and laboratory research on hepatitis B viral suppression and liver-targeted antiviral therapy.
?? For laboratory and research use only.?Please consult staff for other specifications and uses?

EMI starting from $0.00/month - View Plans
Compare

Description

Pradefovir is an innovative liver-targeted nucleotide prodrug of adefovir that inhibits HBV reverse transcriptase, demonstrating potent and specific antiviral effects. It remains stable in plasma and GI, activated in the liver via CYP3A4, leading to lower systemic exposure and improved safety. Clinical studies show efficacy equivalent to tenofovir disoproxil with fewer renal/bone side effects.


Pradefovir Mesylate Tablets Product Specifications

ParameterDetails
Product NamePradefovir Mesylate Tablets (Xinshumu)
Generic NamePradefovir Mesylate
CAS Number625095?60?5
Molecular FormulaC??H??ClN?O?P
Molecular Weight~423.8?g/mol
Strength45?mg per tablet (based on C??H??ClN?O?P)
Pack Size30 tablets per bottle
Dosage FormOral film-coated tablet
Approval No.H20240036 (NMPA)
Drug Code86909589000053
ManufacturerXi’an Gelan Xintong Pharmaceutical Co., Ltd.
Barcode6976282808051
Storage ConditionsStore <25?°C, sealed, protected from light and moisture
Intended UseLaboratory or preclinical HBV antiviral research

Pradefovir Mesylate Tablets Mechanism of Action

Pradefovir is a liver-directed prodrug that converts via CYP3A4 to adefovir, which inhibits HBV DNA polymerase, effectively blocking viral replication. Its hepatoselective design reduces systemic exposure and enhances safety.


Pradefovir Mesylate Tablets Research Applications

  • Chronic HBV replication suppression

  • Pharmacokinetic and pharmacodynamic profiling in liver-targeted therapy

  • Resistance and safety comparison with first-line antiviral agents

  • Preclinical studies on long-term antiviral efficacy and toxicity


Safety & Handling

  • Handling: Use PPE—gloves, lab coat, goggles—avoid ingestion and contact.

  • Storage: Keep sealed below 25?°C in a dry, light-protected environment.

  • Precautions: For laboratory use only; not for human or veterinary administration.


Core Keywords

pradefovir tablets, pradefovir mesylate 45mg, CAS 625095?60?5, H20240036, antiviral prodrug, liver targeted HBV drug, Xinshumu pradefovir, wholesale pradefovir


Research Use Disclaimer

For laboratory and preclinical research use only. Not approved for clinical, therapeutic, diagnostic, or veterinary applications. Misuse may pose health or regulatory risks. Use under authorized institutional protocols.

Additional information

Weight1 kg
Dimensions26 × 21 × 26 cm

1 review for Pradefovir Mesylate Tablets 45?mg (Xinshumu)

  1. jim

    La logistica è veloce e il pacco è arrivato. L’effetto è buono.

Add a review

Your email address will not be published. Required fields are marked *

EMI Options

Select at least 2 products
to compare